Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of long-acting octreotide injection versus Sandostatin in GEP-NET
CTR20242030Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of octreotide, Octreotide long-acting injection in Gastroenteropancreatic Carcinoid Tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Aug 2024; status: active.
02
Drugs
octreotideOctreotide long-acting injection
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20242030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242030.